Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapies for metabolic and endocrine disorders, including obesity and liver disease.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Ancora | 40 | Added +235% | 570 | $22,236 | 0.0% |
| Paul Tudor Jones / Tudor | 63 | Added +269% | 287,331 | $11,208,782 | 0.0% |
| Steve Cohen / Point72 | 76 | Added +2577% | 508,608 | $19,840,798 | 0.0% |
| Bridgewater | 56 | Added +23% | 87,859 | $3,427,380 | 0.0% |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-09-24.